Products with Anti-platelet aggregation bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3677 | Mulberrofuran A |
| 1. Mulberrofuran A can inhibit the formations of 12-hydroxy-, 8, 10-heptadecatrienoic acid (HHT) and thromboxane B2, but it can increase the formation of 12-hydroxy-5, 8, 10, 14-eicosatetraenoic acid (12-HETE). | |
| BCN3833 | Panaxynol |
| Panaxynol is the most potent antiplatelet agent in ginseng and its mechanism of action is chiefly due to the inhibition of thromboxane formation. Panaxynol has neuroprotective, and anti-proliferative effects, it induces neurite outgrowth in PC12D cells via cAMP- and MAP kinase-dependent mechanisms, and protects cortical neurons from ischemia-like injury by up-regulation of HIF-1alpha expression and inhibition of apoptotic cascade. Panaxynol has inhibitory effects on the proliferation of human pancreatic cancer cell PANC-1through inhibiting cell division and down-regulating Ki67 expression. | |
| BCN3853 | Notoginsenoside Fc |
| Notoginsenoside Fc has perfect anti-platelet aggregatory effect. | |
| BCN3909 | Decuroside I |
| Decuroside I shows weak inhibiting activity against the primary and secondary wave aggregation of human platelet. | |
| BCN3933 | Paeoniflorigenone |
| 1. Paeoniflorigenone is a depolarizing neuromuscular blocking agent, being similar to succinylcholine. 2. Paeoniflorigenone is cytotoxic and induces apoptosis selectively in the cancer cell lines. 3. Paeoniflorigenone may take part in improving blood circulation by inhibiting ether platelet aggregation and/or blood coagulation. 4. Paeoniflorigenone shows anti-inflammatory effects. | |
